Stock MIRA MIRA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News MIRA Pharmaceuticals, Inc.

Equities

MIRA

US60458C1045

Market Closed - Nasdaq
Other stock markets
 21:30:00 28/05/2024 BST 		5-day change 1st Jan Change
0.8501 USD -3.94% Intraday chart for MIRA Pharmaceuticals, Inc. +0.01% -19.04%
05-20 Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog CI
05-13 MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
PR
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, A Differentiated Oral Ketamine Analog
CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
PR
Mira Pharmaceuticals, Inc. Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
CI
MIRA Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
PR
Mira Pharmaceuticals Inc. Announces Appointment of Itzchak Angel as Chief Scientific Advisor
CI
MIRA Pharmaceuticals, Inc. Announces Management Changes
CI
MIRA Pharmaceuticals, Inc. Provides Updated Information Regarding the Patented, Pre-Clinical Drug Candidate Molecule Known as Mira1a
CI
MIRA Pharmaceuticals Provides Corporate Update
PR
Certain Stock Options of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.
CI
Certain Common Stock of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.
CI
Certain Warrants of MIRA Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-JAN-2024.
CI
MIRA Pharmaceuticals, Inc. Announces Resignation of Christos Nicholoudis from the Board of Directors and as Part-Time General Counsel
CI
MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence Simulations
PR
MIRA Pharmaceuticals, Inc. Releases Breakthrough Data from Artificial Intelligence Simulations
CI
MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
PR
MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MIRA Stock
  4. News MIRA Pharmaceuticals, Inc.